Person: ÖZTÜRK CİVELEK, DİLEK
19 results
Search Results
Now showing 1 - 10 of 19
Publication Metadata only Dosing-Time Dependent Reproductive Toxicity of Everolimus in Male Mice.(2016-05-25) Öztürk, Narin; ÖZTÜRK, DİLEK; Pala Kara, Zeliha; Kaptan, Engin; Li, Xiao Mei; Levi, Francis; Okyar, Alper; ÖZTÜRK CİVELEK, DİLEKPublication Metadata only SS-73: Everolimusun kronofarmakokinetiği: Uygulama zamanı, cinsiyet ve beslenme durumunun etkisi(2019-11-03T00:00:00Z) Öztürk, Ferdi; ÖZTÜRK, DİLEK; Yasemin Kübra, Akyel; PALA KARA, ZELİHA; OKYAR, ALPER; ÖZTÜRK CİVELEK, DİLEKPublication Metadata only PS-01: Zamana bağlı everolimus uygulamasının dişi ve erkek farelerde P-glikoprotein ekspresyonuna etkisi(2019-11-03T00:00:00Z) Öztürk, Ferdi; Yasemin Kübra, Akyel; ÖZTÜRK, DİLEK; ÖZTÜRK, NARİN; PALA KARA, ZELİHA; OKYAR, ALPER; ÖZTÜRK CİVELEK, DİLEK; GÖNCÜ, BEYZA SERVETPublication Metadata only Synthesis and Cytotoxic Activity of Coumarin-Thymol Derivatives(2018-06-30) ZENGİN KURT, BELMA; Çelebi, Gülşen; ÖZTÜRK, DİLEK; SONMEZ, FATIH; ZENGİN KURT, BELMA; ÖZTÜRK CİVELEK, DİLEKPublication Metadata only Evaluation of Metabolites Produced by Fungal Biotransformation of Apigenin and Fisetin and Their Cytotoxic Activities(2020-03-01T00:00:00Z) GAZİOĞLU, IŞIL; Erdoğan, Oğuz; YANIKOĞLU, RABİA SARE; ÖZTÜRK, DİLEK; GAZİOĞLU, IŞIL; YANIKOĞLU, RABİA SARE; ÖZTÜRK CİVELEK, DİLEKPublication Metadata only Circadian Rhythms and Chronopharmacology of Drugs(2015-11-29) ÖZTÜRK, DİLEK; Okyar, Alper; ÖZTÜRK CİVELEK, DİLEKPublication Metadata only HT-29 Kolon Kanser Hücre Hattında Senkronizasyon Başlatıcıların Sirkadiyen Ritimdeki Rolü(2019-12-01) Göncü, Beyza; ÖZTÜRK, DİLEK; ÖZTÜRK CİVELEK, DİLEK; GÖNCÜ, BEYZA SERVETPublication Metadata only Evaluation of the Metabolites Produced by Microbial Biotransformation of Diosmin by Enterococcus gallinarum ATCC 49573 and Investigation of Their Cytotoxic Effects on HEK293 Cell Line,(2020-09-24T00:00:00Z) GAZİOĞLU, IŞIL; YILDIRIM, KUDRET; ÖZTÜRK, DİLEK; Erdoğan, Oğuz; Zengin, Ozge Sultan; GAZİOĞLU, IŞIL; ÖZTÜRK CİVELEK, DİLEKPublication Metadata only P-glycoprotein mediated pharmacokinetic interaction between talinolol and barnidipine(2016-06-30) OZTURK, N.; ÖZTÜRK, DİLEK; PALA-KARA, Z.; OKYAR, ALPER; ÖZTÜRK CİVELEK, DİLEKPublication Metadata only Evaluation of the association of SNP in carboxylesterase enzyme (CES1) with pharmacokinetic and adverse effects of capecitabine in breast and colorectal cancer patients(2019-08-01) ÖZTÜRK, DİLEK; Yuksel, Merve Kurtan; Oztas, Ezgi; Ozhan, Gul; Turker, Aylin Altanlar; Korkmaz, Taner; Okyar, Alper; Kara, Zeliha Pala; ÖZTÜRK CİVELEK, DİLEKCapecitabine is an oral prodrug and converted to 5-fluorouracil using three-step enzymatic pathways which include carboxylesterase (CES). Interindividual differences in the activities of drug-metabolizing enzymes may affect efficacy and toxicity. The aim of this study is to evaluate the association of Single nucleotide polymorphisms (SNP) in CES1 with the pharmacokinetic and adverse effects of capecitabine. Plasma samples were obtained from 7 breast and colorectal cancer patients who were treated with capecitabine-based chemotherapy (1000-1250 mg/m(2)) at 0.5, 1, 2, 3 and 4 hours following drug administration on their first day of the first cycle. The plasma concentrations of the capecitabine were determined by using a high-pressure liquid chromatography-UV detector. SNP (rs8192950) was genotyped using the reverse transcription-polymerase chain reaction. Patients were found to have heterozygote (57%), wild (29%), and mutant (14%) distributions of genotypes (p=0.909). The mean plasma area under the curve (AUC(0-4h)) was 4.60 +/- 2.25 mu g.h/mL, and maximum plasma concentration (C-max) was 3.19 +/- 2.5 mu g/mL. There were no statistically significant differences between genotypes and AUC values (p=0.2236) and the most frequently observed side effects were diarrhea (p=0.1028), asthenia (p=0.6456), anemia (p=0.6456), emesis (p=0.3499). This is the first study evaluating an association of genetic variation in CES1 (rs8192950) with pharmacokinetic and adverse effects of capecitabine. Therefore, additional study in larger groups of patients is required to support our study.